Clinical Trial Update: Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating oregovomab and pegylated liposomal doxorubicin (PLD) in patients with PARP inhibitor–resistant ovarian, fallopian tube, o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Oregovomab (oregovomab)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Yonsei University | Conditions: PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | Phase 2 | Status: UNKNOWN